The Peptide NewsroomPeptide research, industry and supply-chain headlines

Sermorelin Goes Mainstream on Telehealth, but the Dosing and Efficacy Data Are Missing

Sermorelin is a short chain of amino acids that stimulates the body's release of growth hormone. It has spent years in the gray zone of longevity clinics and compounding pharmacies, and as of November 2026 it is being sold at national telehealth scale, which makes it worth laying out what is actually documented about it and what is not.

What it is and how it is marketed

Sermorelin works by stimulating growth-hormone release, and it is marketed for recovery, body composition and anti-aging, according to CNBC's reporting on the compound. Those three marketing categories are doing a lot of work: none of them is a regulatory indication, and CNBC notes that the compounded formulations now being sold are not approved by the Food and Drug Administration.

Why it is suddenly available

The shift is regulatory, not scientific. The Health and Human Services Department issued a policy in October saying the FDA will not take enforcement action against licensed pharmacies, federal facilities or physicians that compound and dispense six unapproved peptides while formal rules are reviewed, which in practice opened the door without granting approval of the peptides themselves.

Where it is being sold now

Sermorelin is one of five compounded formulations in the Peptides+ platform Hims and Hers launched across the U.S., alongside NAD+, glutathione, vitamin B-12 and L-carnitine, with at-home blood collection and ongoing clinical oversight. More than 10,000 people signed up for the early access list within 15 days, a company spokesperson told CNBC.

What Isn't Established

Almost everything downstream of the mechanism. Hims chief medical officer Dr. Anant Vinjamoori told CNBC the company has more to learn about how best to use the peptides and how effective they are, saying "we don't have all of this data that we're used to having with compounds like this." Paul Knoepfler of UC Davis Health put the gap more bluntly: "the dosing for these products really has not been established." Joshua Kritzer of Tufts added that without large clinical trials, researchers cannot rule out rare but serious complications. Neither source cites a single human outcome trial on sermorelin.

The state of the evidence

There is a plausible mechanism, a regulatory opening, a distribution channel reaching millions, and no published efficacy data in either source. That is an unusual order of operations, and the company selling it says so itself.

Sources: RSS.app — Renewal bundle (read), RSS.app — Peptides bundle (read).

Filed under: explainer, fda, celebrity

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

FDA's Peptide Compounding Shakeup Blurs Drug and Supplement Lines, and Legitimate Brands Are Exposed

New Hope Network reports that FDA's shifting peptide compounding rules have left gray-market injectables like BPC-157 and TB-500 in regulatory limbo, while some supplement brands sell them under a Supplement Facts panel. Industry lawyers call that illegal, and legitimate peptide brands may pay the reputational bill.

What the Research Actually Says About Semaglutide, From Weight Loss to Memory

Semaglutide has large human trials behind its weight and metabolic outcomes, but the newer questions about energy expenditure, muscle preservation and cognition are far less settled. A digest of what researchers have actually reported, and where the evidence stops.

Hers Launches Peptides+ Platform, But Its Headline Peptides Are Still Waiting on the FDA

Telehealth provider Hers launched a longevity vertical called Peptides+ with sermorelin, glutathione, NAD+, L-Carnitine and B12, telling Glossy it will add BPC-157 and TB-500 as soon as regulations allow. A company-commissioned survey found 55% of U.S. adults are curious about peptide therapies while 9% use them, and no clinical data on the launch compounds appears in the interview.